Neumora Therapeutics (NASDAQ: NMRA) — Company Overview, News & Financial Data
Neumora Therapeutics is a biotechnology company developing precision medicines for neurological disorders and improving patient outcomes.
Neumora Therapeutics
Neumora Therapeutics (NASDAQ:NMOR) is a biotechnology company focused on developing therapies for brain diseases. This innovative firm zeros in on precision medicines designed to target the underlying causes of neurological disorders, aiming to bring transformative treatments to patients suffering from conditions such as depression, schizophrenia, and Parkinson's disease. By leveraging advanced data analytics and neuroscience, Neumora Therapeutics is dedicated to pushing the boundaries of what's possible in mental health care. Their projects span various stages of drug development, from discovery through clinical trials, with the overarching objective to significantly improve outcomes for individuals battling serious brain diseases.
Snapshot
Operations
Products and/or services of Neumora Therapeutics
- Development of precision medicines targeting brain circuit dysfunctions for neurological and psychiatric disorders.
- Creation of advanced diagnostic tools for accurate and early detection of neuropsychiatric conditions.
- Implementation of AI and machine learning technologies to identify new drug targets and biomarkers for brain diseases.
- Collaboration with academic and industry partners to accelerate drug discovery and development processes.
- Offering a platform for patient engagement and personalized treatment plans based on genetic and biomarker data.
- Conducting large-scale clinical trials to validate the efficacy and safety of novel therapeutic candidates.
Neumora Therapeutics executive team
- Paul L. BernsExecutive Chairman
- Joshua PintoPresident, CEO & Director
- Daljit Singh AuroraChief Operationg & Development officer
- Michael Lee MilliganCFO & Principal Accounting Officer
- Nicholas BrandonChief Scientific Officer
- Pablo GersbergChief Information Officer
- Jason G. DuncanChief Legal & Administrative Officer
- Helen RubinsteinHead of Investor Relations
- Amy SullivanChief Human Resources Officer
- David PhillipsSenior Vice President & Head of Quality
Latest news about Neumora Therapeutics
Neumora Q2 net loss narrows to $43.1m
United StatesNeumora Therapeutics reports favorable 162-animal toxicology results
United StatesNeumora Therapeutics reports Q4 and FY financial results and clinical program updates
United StatesNeumora’s Alzheimer’s candidate slashes agitation scores in early trial
United States
Key financials
Reported results for Neumora Therapeutics , in USD.
- Market cap
- 73.9M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.2
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -241.2M | -236.9M | |
| 0 | -263.5M | -243.8M | |
| 0 | -188.2M | -235.9M | |
| 0 | -135.9M | -130.9M |